Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. (Q46948937)
Jump to navigation
Jump to search
scientific article published in September 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. |
scientific article published in September 2007 |
Statements
Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders (English)
Perzborn E
Kubitza D
1 September 2007